| 【Fixed Income Research】CENCHI - Buy on CENCHIs |
| 【Company Research】Smoore Int’l (6969 HK) – Overseas order and the new disposable vape to sustain growth throughout 2022E |
| 【Sector Research】China Auto Sector – Strong NEV sales recovery in May |
| 【Sector Research】China Auto Sector – Purchase-tax cut exceeds our expectation |
| 【Company Research】Topsports (6110 HK) – Drags are expected, turnaround in 2H23E likely |
| 【Fixed Income Research】eHi Car Services: Weak 1Q22 results partly due to limited used car disposal |
| 【Sector Research】China Technology Sector – China TMT Hardware barometer |
| 【Company Research】Baozun (BZUN US) – VAS enrichment & resilient GMV ahead |
| 【Company Research】Pinduoduo (PDD US) – Well positioned for upcoming recovery |
| 【Company Research】I-Mab BioPharma (IMAB US) – Uliledlimab (CD73) showed preliminary efficacy in treatment-naïve advanced NSCLC patients |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
